Description
欢迎收听今日医学焦点！一项突破性研究关注于tarlatamab，这是一种针对小细胞肺癌患者的最新双特异性T细胞引导免疫疗法。DeLLphi-301试验显示，每两周一次的10mg剂量治疗能够带来持久反应和生存益处。然而，常见的副作用包括细胞因子释放综合征、发热、食欲下降等，通常在第一或第二次给药后出现，并可通过支持性护理管理。作为首款获批治疗小细胞肺癌的T细胞引导疗法，了解并管理这些副作用至关重要。下一期节目，我们将深入探讨这些发现及其对患者护理的影响。不要错过！
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare
The method of invention, AI's new clock speed and why capital markets are confused
05 Dec 2025
Azeem Azhar's Exponential View
Meta Stock Surges on Plans for Metaverse Cuts
05 Dec 2025
Bloomberg Tech